JUNS
NASD Jupiter Neurosciences, Inc.$2.77 ↑ +0.00 (+0.00%) Trading Up from the previous close of $2.77, $0.08 below the day’s high of $2.85
- YTD change
- -96.38%
- vs 20-day SMA
- -1.94%
- vs 200-day SMA
- -89.73%
Price ranges
Price & Performance
+2.47 (+662.62%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 99.8% away from all-time highs of $1,463.25
- JUNS is down 96% since the beginning of the year
- JUNS is down 98% over the past 12 months
- JUNS is down 10% over the past 1 month
- 5% of all JUNS investors are betting against JUNS
JUNS reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is +78.6%.
- Previous minute
- -$0.02
- Last hour
- -$0.02
- Last 5 days
- +13.52%
- vs 8-day SMA
- +7.05%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company engaged in treating neuroinflammation with a current focus on CNS disorders and rare diseases. The firm offers JOTROL, an enhanced orally administered resveratrol formulation, designed to deliver therapeutically relevant, safe levels of resveratrol. The company was founded by Christer Rosén, Alexander Rosén, Claes Wahlestedt, Marshall Hayward, and Shaun P. Brothers in January 2016 and is headquartered in Jupiter, FL.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.